Arsenal Medical announced late-breaking results from the EMBO-02 first-in-human (FIH) clinical study, which is evaluating the ...

This article is Part Two of a three-part community health series presented in partnership with Southern Kentucky Vascular, Somerset.

Arsenal Medical, a clinical-stage company developing innovative biomaterial-based devices, announced late-breaking results from the EMBO-02 clinical study. In EMBO-02, NeoCast™, a shear-responsive, ...

While some research has shown benefits for patients who qualify, questions remain about the therapy's long-term risks and use among men without a medical need.